Inhibrx Biosciences
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,300 | $0 | $100 | $0 |
Gross Profit | 638 | -675 | -589 | -761 |
EBITDA | -27,389 | -39,947 | -47,176 | -43,104 |
EBIT | -28,050 | -40,622 | -47,865 | -43,864 |
Net Income | -28,654 | -43,311 | -47,865 | -43,864 |
Net Change In Cash | 1,300 | 0 | 100 | 0 |
Free Cash Flow | -29,953 | -35,916 | -43,736 | -30,528 |
Cash | 186,567 | 216,520 | 152,596 | 196,332 |
Basic Shares | 15,468 | 15,468 | 14,475 | 15,468 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $200 | $1,800 | $2,192 | $7,125 |
Gross Profit | -2,085 | 609 | -107,994 | 4,437 |
EBITDA | 1,703,350 | -206,693 | -125,817 | -75,369 |
EBIT | 1,701,065 | -207,884 | -127,042 | -76,564 |
Net Income | 1,687,572 | -241,361 | -145,226 | -81,768 |
Net Change In Cash | 200 | 1,800 | 2,192 | 7,125 |
Free Cash Flow | -197,006 | -197,902 | -115,987 | -81,187 |
Cash | 152,596 | 277,924 | 273,865 | 131,301 |
Basic Shares | 14,475 | 47,130 | 40,108 | 38,010 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.85 |
2025-03-31 | -$2.80 |
2024-12-31 | -$4.47 |
2024-09-30 | -$2.84 |
